Fig. 4From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patientsProbabilistic sensitivity analysis cost-effectiveness scatterplots for IDegLira compared with the degludec based on DUAL II China. The red line represents a WTP of CNY 257,094 per QALY gained. QALY, quality-adjusted life-year; CNY, Chinese yuan; WTP, willingness to payBack to article page